MedPath

Acceptance and Commitment Therapy (ACT) in Groups for Obsessive Compulsive Disorder: A Clinical Trial in Brazil

Not Applicable
Active, not recruiting
Conditions
Obsessive-Compulsive Disorder
Interventions
Other: Group acceptance and commitment therapy (ACT)
Registration Number
NCT06548893
Lead Sponsor
Universidade Federal do Paraná
Brief Summary

The goal of this clinical trial is to learn if Acceptance and Commitment Therapy (ACT) + Exposure and Response Prevention (ERP) in Group is effective to Obsessive Compulsive Disorder (OCD) in adults.

Researchers will compare intervention to control group to see if those who attend the group therapy have better results than control group.

Participants will go through a 16-week group therapy based on a protocol designed by Michael Twohig (Twohig et al, 2018).

* Participants will not have any medication adjustment during therapy

* Participants will be assessed 3 times throughout the therapy, plus an assessment in a 6-month follow-up.

Detailed Description

The goal of this clinical trial is to learn if Acceptance and Commitment Therapy (ACT) + Exposure and Response Prevention (ERP) in Group is effective to Obsessive Compulsive Disorder (OCD) in adults. The main questions it aims to answer are:

* Can ACT in groups help decrease the severity of OCD symptoms?

* Can ACT in groups help increase psychological flexibility in this group?

* Can ACT in groups help increase quality of life in this group?

Researchers will compare intervention (n=16) to control group (n=8) to see if those who attend the group therapy have better results than control group.

We will perform an unequal randomization in a 2:1 ratio, in blocks of 6, for allocation to each group. The assessor of the outcomes of interest will be blinded to the group to which the participant was assigned

Participants will go through a 16-week group therapy based on a protocol designed by Michael Twohig (Twohig et al, 2018).

* Participants will not have any medication adjustment during therapy

* Participants will be assessed 3 times throughout the therapy, plus an assessment in a 6-month follow-up.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
24
Inclusion Criteria
  • OCD diagnosis according to DMS-5/ Minimum score of 20 in YBOCS
Exclusion Criteria
  • Psychotic disorder, maniac episode, intellectual disability, Chemical dependency, Suicidal risk, another current psychotherapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group psychotherapy with ACTGroup acceptance and commitment therapy (ACT)16 sessions of group psychotherapy based on ACT + exposure with response prevention (EPR)
Primary Outcome Measures
NameTimeMethod
Yale-Brown Obsessive-Compulsive Scale (YBOCS)10 months (4-month intervention + 6-month follow-up)

Measure for assessing the presence and severity of obsessive-compulsive disorder (OCD) symptoms.

Secondary Outcome Measures
NameTimeMethod
Depression Anxiety and Stress Scale (DASS)10 months (4-month intervention + 6-month follow-up)

Set of self-report scales designed to measure the emotional states of depression, anxiety and stress.

Affective Style Questionnaire (ASQ)10 months (4-month intervention + 6-month follow-up)

Brief instrument to measure individual differences in emotion regulation

AAQ for Obsessions and Compulsions (AAQ-OC)10 months (4-month intervention + 6-month follow-up)

Self-report measure of experiential avoidance in response to unwanted intrusive thoughts.

Acceptance and Commitment Therapy Processes (CompACT)10 months (4-month intervention + 6-month follow-up)

Measure of psychological flexibility

Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-SV)10 months (4-month intervention + 6-month follow-up)

Measures of the degree of enjoyment and satisfaction experienced by subjects in various areas of dally functioning

Clinical Global Impressions (CGI) Scale,10 months (4-month intervention + 6-month follow-up)

Quantify and track patient progress and treatment response over time.

Trial Locations

Locations (1)

Universidade Federal Do Paraná

🇧🇷

Curitiba, Parana, Brazil

© Copyright 2025. All Rights Reserved by MedPath